Make your one-time, tribute, or recurring online gift to support brain tumour patient programs and research today: Donate
Dr. Sabine Mai
Manitoba Institute of Cell Biology, Winnipeg, MB
The proposed study focuses on ependymoma, a childhood brain tumour. At diagnosis, it is not possible to know which child will respond to treatment and which child will recur, i.e. if prognosis is favourable or non-favourable. We have developed quantitative tools that may allow for the distinction of good and poor responders at diagnosis.
These tools involve three-dimensional (3D) imaging of telomeres. Telomeres are the ends of chromosomes; they protect the chromosomes from damage and prevent recombination and fusion with other chromosomes (Mai, 2010). Telomere dysfunction therefore is associated with genomic instability and found in many cancers (Mai and Garini, 2006; Mai, 2010).
The data obtained in this study are quantitatively measured, and the output is expected to be a 3D nuclear telomeric profile of each child’s tumour, indicative of favourable or non-favourable disease and will, in the near future, enable for the first time a choice for specific treatments for each child’s ependymoma.
The best Christmas gift I could get would be to get this lump of coal out of my head. However, I do have good days. And recently, a lot more good days than bad. This is how I know that I will overcome this. This is how I know that my “new normal” won’t be so bad. One day at a time, and counting everything I am grateful for along the way.Learn more
Stephen was diagnosed with an anaplastic oligodendroglioma (grade III) in November of 2015 at the age of 53 years old, and shares his...Learn more
When you look back at Brain Tumour Foundation of Canada’s history, it’s clear that at the heart of the organization are the patients,...Learn more